About: Vatelizumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.

Property Value
dbo:abstract
  • Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy. (en)
dbo:casNumber
  • 1238217-55-4
dbo:fdaUniiCode
  • A4R7G50030
dbo:wikiPageID
  • 33052103 (xsd:integer)
dbo:wikiPageLength
  • 2428 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 992866613 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:casNumber
  • 1238217 (xsd:integer)
dbp:chemspiderid
  • none (en)
dbp:mabType
  • mab (en)
dbp:source
  • zu (en)
dbp:target
dbp:type
  • mab (en)
dbp:unii
  • A4R7G50030 (en)
dbp:verifiedfields
  • changed (en)
dbp:verifiedrevid
  • 470629425 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy. (en)
rdfs:label
  • Vatelizumab (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License